Before revision: Medical uses Delandistrogene moxeparvovec is indicated for the treatment of ambulatory children aged four through five years of age with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.
After revision: Medical uses Delandistrogene moxeparvovec is indicated for the treatment of ambulatory and non-ambulatory individuals four years of age with Duchenne muscular dystrophy with a confirmed mutation in the Duchenne muscular dystrophyand older gene.